These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 32759060

  • 1. Influence of valproate-induced hyperammonemia on treatment decision in an adult status epilepticus cohort.
    Habhab SF, Ulvin LB, Taubøll E, Svalheim S, Olsen KB, Horn MA, Heuser K.
    Epilepsy Behav; 2020 Oct; 111():107193. PubMed ID: 32759060
    [Abstract] [Full Text] [Related]

  • 2. Hyperammonemia in Patients With Status Epilepticus Treated With or Without Valproic Acid.
    Smith KM, Britton JW, Hocker SE, Toledano M.
    Neurologist; 2021 May 05; 26(3):80-82. PubMed ID: 33942787
    [Abstract] [Full Text] [Related]

  • 3. Hyperammonemia following intravenous valproate loading.
    DeWolfe JL, Knowlton RC, Beasley MT, Cofield S, Faught E, Limdi NA.
    Epilepsy Res; 2009 Jul 05; 85(1):65-71. PubMed ID: 19299111
    [Abstract] [Full Text] [Related]

  • 4. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA, Abdella MM.
    Epilepsy Res; 2009 Sep 05; 86(1):32-41. PubMed ID: 19446440
    [Abstract] [Full Text] [Related]

  • 5. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
    Tseng YL, Huang CR, Lin CH, Lu YT, Lu CH, Chen NC, Chang CC, Chang WN, Chuang YC.
    Medicine (Baltimore); 2014 Sep 05; 93(11):e66. PubMed ID: 25192484
    [Abstract] [Full Text] [Related]

  • 6. Gait instability in valproate-treated patients: Call to measure ammonia levels.
    Kipervasser S, Elger CE, Korczyn AD, Nass RD, Quesada CM, Neufeld MY.
    Acta Neurol Scand; 2017 Nov 05; 136(5):401-406. PubMed ID: 28436001
    [Abstract] [Full Text] [Related]

  • 7. Differential ammonia decay kinetics indicates more than one concurrent etiological mechanism for symptomatic hyperammonemia caused by valproate overdose.
    Mojumder DK, De Oleo RR.
    Indian J Pharmacol; 2014 Nov 05; 46(3):345-7. PubMed ID: 24987188
    [Abstract] [Full Text] [Related]

  • 8. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
    Yamada H, Shishido T, Mukai T, Araki M, Naka H, Tokinobu H.
    Rinsho Shinkeigaku; 2019 May 28; 59(5):258-263. PubMed ID: 31061301
    [Abstract] [Full Text] [Related]

  • 9. Intravenous use of valproic acid in status epilepticus is associated with high risk of hyperammonemia.
    Lind J, Nordlund P.
    Seizure; 2019 Jul 28; 69():20-24. PubMed ID: 30953957
    [Abstract] [Full Text] [Related]

  • 10. Valproic Acid-Associated Hyperammonemia: A Systematic Review.
    Wong YJ, Fan J, Wan A, Mihic T, Gnyra M.
    J Clin Psychopharmacol; 2019 Jul 28; 43(3):283-294. PubMed ID: 37126830
    [Abstract] [Full Text] [Related]

  • 11. Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study.
    Chen WB, Gao R, Su YY, Zhao JW, Zhang YZ, Wang L, Ren Y, Fan CQ.
    Eur J Neurol; 2011 Dec 28; 18(12):1391-6. PubMed ID: 21557791
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of intravenous valproate for status epilepticus: a systematic review.
    Trinka E, Höfler J, Zerbs A, Brigo F.
    CNS Drugs; 2014 Jul 28; 28(7):623-39. PubMed ID: 24806973
    [Abstract] [Full Text] [Related]

  • 13. Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy.
    Kwack DW, Kim DW.
    Clin Neurol Neurosurg; 2023 Oct 28; 233():107962. PubMed ID: 37717359
    [Abstract] [Full Text] [Related]

  • 14. Incidence, Presentation, and Risk Factors for Sodium Valproate-Associated Hyperammonemia in Neurosurgical Patients: A Prospective, Observational Study.
    Woo PYM, Woo AWY, Lam SW, Ko NMW, Ho JWK, Chu ACH, Kwan MCL, Chan Y, Wong HT, Chan KY.
    World Neurosurg; 2020 Dec 28; 144():e597-e604. PubMed ID: 32916358
    [Abstract] [Full Text] [Related]

  • 15. CPS1 T1405N polymorphism, HDL cholesterol, homocysteine and renal function are risk factors of VPA induced hyperammonemia among epilepsy patients.
    Chen L, Tian Q, Zhang M, Chen D, Gao X, Yang H, Li H, Li C, Wen J, Li Y, Tian X, Chen P.
    Epilepsy Res; 2019 Aug 28; 154():139-143. PubMed ID: 31151073
    [Abstract] [Full Text] [Related]

  • 16. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.
    Yamamoto Y, Takahashi Y, Suzuki E, Mishima N, Inoue K, Itoh K, Kagawa Y, Inoue Y.
    Epilepsy Res; 2012 Sep 28; 101(3):202-9. PubMed ID: 22542569
    [Abstract] [Full Text] [Related]

  • 17. Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey.
    Hosseini H, Shafie M, Shakiba A, Ghayyem H, Mayeli M, Hassani M, Aghamollaii V.
    Psychopharmacology (Berl); 2023 Jan 28; 240(1):149-156. PubMed ID: 36459199
    [Abstract] [Full Text] [Related]

  • 18. Risk factors for valproic acid induced hyperammonemia and its association with cognitive functions.
    Duman B, Can KC, Ağtaş-Ertan E, Erdoğan S, İlhan RS, Doğan Ö, Kumbasar H, Çamsarı UM.
    Gen Hosp Psychiatry; 2019 Jan 28; 59():67-72. PubMed ID: 31276904
    [Abstract] [Full Text] [Related]

  • 19. Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy.
    Velioğlu SK, Gazioğlu S.
    Acta Neurol Scand; 2007 Aug 28; 116(2):128-32. PubMed ID: 17661800
    [Abstract] [Full Text] [Related]

  • 20. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
    Inoue K, Takahashi T, Yamamoto Y, Suzuki E, Takahashi Y, Imai K, Inoue Y, Hirai K, Tsuji D, Itoh K.
    Seizure; 2015 Dec 28; 33():76-80. PubMed ID: 26599579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.